second generation cephalosporin

PreclinicalSmall molecule

second generation cephalosporin is one of 48 small molecule programs targeting Achalasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AchalasiaActive, not recruiting

PneumoniaActive, not recruiting

AchalasiaPreclinical

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

155 competitors in Pneumonia

#DrugCompanyPhaseTrials

Jakafi

Incyte

Preclinical

1 2

Primaquine

Sanofi

Preclinical

1 3

Acanya

Pfizer

Preclinical

1 4

Prevacid

Takeda

Preclinical

1 5

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 6

Innohep

Jazz Pharmaceuticals

Preclinical

1 7

Avlosulfon

AAlmirall, S.A.

Preclinical

4 8

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 9

Advil

KKenvue Brands

Preclinical

2 10

Zantac 150

CChattem

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia1 trial

Effectiveness Study of Integrative Treatment for Pediatric Community Acquired Pneumonia

Unknown status·LLiaoning University of Traditional Chinese Medicine·N/A·NCT02362906·1,500 enrolled

Achalasia1 trial

Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT01750385·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for second generation cephalosporin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — second generation cephalosporin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for second generation cephalosporin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Zhongshan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Zhongshan Hospital

second generation cephalosporin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumonia1 trial

Achalasia1 trial

References

Drug Info

Quick Facts

Related News